Handa Pharmaceuticals Inc.
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-03… Read more
Handa Pharmaceuticals Inc. (6620) - Net Assets
Latest net assets as of : NT$- TWD
Based on the latest financial reports, Handa Pharmaceuticals Inc. (6620) has net assets worth NT$- TWD as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$-) and total liabilities (NT$-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Handa Pharmaceuticals Inc. - Net Assets Trend (None–None)
This chart illustrates how Handa Pharmaceuticals Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Handa Pharmaceuticals Inc. (None–None)
The table below shows the annual net assets of Handa Pharmaceuticals Inc. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Handa Pharmaceuticals Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Handa Pharmaceuticals Inc. Competitors by Market Cap
The table below lists competitors of Handa Pharmaceuticals Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PlayNitride Inc.
TW:6854
|
$241.78 Million |
|
Guangdong Decro Film New
SHE:001378
|
$241.78 Million |
|
Karat Packaging Inc
NASDAQ:KRT
|
$241.81 Million |
|
Marssenger Kitchenware Co. Ltd.
SHE:300894
|
$241.91 Million |
|
Sichuan Huiyuan Optical Com
SHE:000586
|
$241.69 Million |
|
GnCenergy Co Ltd
KQ:119850
|
$241.68 Million |
|
Mirae Asset Venture Investment Co. Ltd
KQ:100790
|
$241.66 Million |
|
Hubei Huaqiang High-Tech Co. Ltd. A
SHG:688151
|
$241.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Handa Pharmaceuticals Inc.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Handa Pharmaceuticals Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Handa Pharmaceuticals Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Handa Pharmaceuticals Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,528,453,600
- Average return on equity (ROE) among peers: 3.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Handa Pharmaceuticals Inc. (6620) | NT$- | N/A | N/A | $241.75 Million |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| Easywell Biomedicals Inc. (1799) | $696.90 Million | -39.00% | 0.68x | $62.14 Million |
| LIWANLI Innovation Co Ltd (3054) | $799.59 Million | 4.48% | 0.55x | $49.55 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |
| TTY Biopharm Co Ltd (4105) | $6.11 Billion | 22.00% | 0.56x | $486.74 Million |